No Detail Found!

Neurotrophic Tyrosine receptor Kinase (NTRK) gene fusion in CNS tumours: A diagnostic key for a novel targeted therapy

Author(s)
Fawaz Mohamed Department of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia; Brain Tumour Unit, King Abdulaziz University, Jeddah, Saudi Arabia
Maher Kurdi Department of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia; Brain Tumour Unit, King Abdulaziz University, Jeddah, Saudi Arabia
Imad Fadl-Elmula Department of Clinical Genetics, Faculty of Medicine, Al-Neelain University,Khartoum,Sudan
Hanadi Talal Ahmedah Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University,Rabigh,Saudi Arabia
Eyad Faizo Division of Neurosurgery, Department of Surgery, Faculty of Medicine, Tabuk University, Tabuk, Saudi Arabia
Ahmad Ali A Fallata Department of Internal Medicine, Faculty of Medicine, University of Tabuk,Tabuk,Saudi Arabia
Tareq S Almaghrabi Department of Internal Medicine, Faculty of Medicine, University of Tabuk,Tabuk,Saudi Arabia
Iman M. Mirza Department of Family and Community Medicine, Faculty of Medicine, University of Tabuk,Tabuk,Saudi Arabia
Shadi Alkhayyat Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University and King Abdulaziz University Hospital,Jeddah,Saudi Arabia
Abstract
The identification of dominant oncogenic mutations with the capability to inhibit their genetic aberrations by specific targeted inhibitors have improved the strategic approach of human cancer diagnosis and management, particularly in those patients who previously received ineffective conventional therapies. Neurotrophic tyrosine receptor kinase (NTRK) gene fusion is one of the newly detected gene mutations at significant frequencies in several solid body tumors and was rarely identified in central nervous system (CNS) tumours. NTRK-gene is a main member of three different genetic subtypes (NTRK1-3), which produce tyrosine kinase proteins (Trk-A, B, and C). The protein receptor expression (Pan-Trk) can generally be detected by immunohistochemistry (IHC) technique however, its confirmation always requires advanced molecular methodologies. Although Pan-Trk immuno staining has been used as an efficient assesing tool for most of non-CNS cancers to detect NTRK-fusion, its utilization in CNS tumour is questionable due to the normal physiological presence of TK receptors in CNS neuropil. This diagnostic pitfall is important as the detection of NTRK-fusion may reflect patient response to Trk-inhibitor. In this review, we described the relationship between NTRK-fusions and Pan-Trk protein in CNS and nonCNS tumours, aided with the previous studies in the literature.
Publication Details
Page(s) 857-865
DOI DOI not available
Published Journal: Bioscience Research, Volume: 19, Issue: 2, Year: 2022

Request the full text from PASTIC

Keywords
Immunohistochemistry, Pan-Trk, NTRK-fusion, CNS tumours
0

Citations

0

Downloads

86

Views